

AD_____

Award Number: W81XWH-12-1-0223

TITLE: Innovative Strategies for Breast Cancer Immunotherapy

PRINCIPAL INVESTIGATOR: Feng Wang-Johanning

CONTRACTING ORGANIZATION: M.D. ANDERSON CANCER CENTER
Houston, TX 77030

REPORT DATE: September 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE September 2013		2. REPORT TYPE Annual		3. DATES COVERED 1 September 2012 - 31 August 2013	
4. TITLE AND SUBTITLE Innovative Strategies for Breast Cancer Immunotherapy				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0223	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Feng Wang-Johanning				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) M.D. ANDERSON CANCER CENTER Houston, TX 77030				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT In our grant application, we detected HERV-K viral particles by transmission electron microscopy (TEM) in sera from an invasive ductal carcinoma (IDC) patient and in BC cell culture media. In fact, HERV-K viral like particles have been found in a variety of tumor cells, as reported by others. These viral particles would be expected to have RT activity. The RT activity of various breast cell culture media was compared, and we found that all cancer cells had higher RT, compared with MCF-10AT cells. In addition, two IBC cell lines (KPL-4 and SUM149) had increased RT activity					
15. SUBJECT TERMS- none provided					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU		19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Project 1.....	4
Project 2.....	6
Project 3.....	10
Project 4.....	11
Project 5.....	13

Project 1: To identify infectious retroviruses in patient specimens:

1.1 Expression of HERV-K *env* mRNA or protein in human inflammatory breast cancer (IBC) cells and tissues: Prior to determination of reverse transcriptase (RT) activity in blood or tissue samples, expression of human endogenous retrovirus type K (HERV-K) *env* RNA and protein was evaluated in additional breast cancer (BC) tissues and cell lines by RT-PCR, western blot, and immunofluorescence (IFS). We found that HERV-K *env* mRNA (Fig. 1A) and protein (Fig. 1B and Fig. 1C) are expressed in IBC cells (SUM-149, KPL-4, and MDA-IBC3) or primary BC biopsies (Acc177, Acc185, Acc168, and Acc204), but not in MCF-10A cells and in normal breast tissues (ND263 and ND273).





Figure 1 (A) The expression of HERV-K *env* type 1 or/and type 2 mRNA (ty1 and ty2) was detected in invasive ductal carcinoma (Acc177, Acc185, Acc168, and Acc204), but not in normal breast tissues (ND263 and ND273) by RT-PCR. β -actin was used as control. **(B)** The expression of HERV-K *env* protein was detected in BC cells (MCF-7, SUM-149, and MDAMB231) but not expressed in MCF-10A benign human breast cells by Western blot using anti-HERV-K mAb (6H5). β -actin was used as control. **(C)** The surface expression of HERV-K (green fluorescence) was demonstrated on malignant cells (KPL-4, MDA-IBC3, and SUM149) by IFS using 6H5. mIgG was used as control.

1.2 We will determine reverse transcriptase (RT) activity in blood or tissue samples: (months 0 to 48)
In our grant application, we detected HERV-K viral particles by transmission electron microscopy (TEM) in sera from an invasive ductal carcinoma (IDC) patient and in BC cell culture media. In fact, HERV-K viral-like particles have been found in a variety of tumor cells, as reported by others²⁻⁵. These viral particles would be expected to have RT activity. The RT activity of various breast cell culture media was compared, and we found that all cancer cells had higher RT, compared with MCF-10A or MCF-10AT cells. In addition, two IBC cell lines (KPL-4 and SUM149) had increased RT activity (Fig. 2). The highest RT activity was demonstrated in density gradient fractions (DGF) 5 to 6 in both cell lines. Importantly, RT activity was demonstrated in RNA, not DNA using SYTO RNA selected stain.



We also found increased RT activity in blood plasma samples from breast cancer patients. RT activity in DGF obtained from various donors including patients with invasive breast cancer (BC), or cancer patients with ductal carcinoma *in situ* (DCIS), or normal female donors was determined (Fig.3). Fraction A (fractions 1 to 5) and B (fractions 6 to 10) were compared between normal donors vs. cancer donors (BC or DCIS). RT units were significantly higher in fraction A (Fig. 3A) or B (Fig. 3B) obtained from BC or DCIS patient plasma, compared with fractions obtained from normal female donors. In addition, RT activity was compared in tumor tissues vs.

uninvolved normal breast tissues obtained from the same donors. Significantly higher RT activity was demonstrated in most tumor tissues compared with matched uninvolved normal breast tissues (Fig. 3C). We reported RT activity in our grant application, and verified this increased activity in additional samples here, including IBC cells; we are preparing a manuscript to report all of these results.




Fig. 3 RT activity was compared in plasma obtained from normal female donors, BC patients, and ductal carcinoma in situ (DCIS) patients or tissues. RT activity was compared in plasma from various female donors including normal donors (N=25), and patients with BC (N=49) and DCIS (N=20). RT activity was significantly higher in BC patients (P=0.0009) and DCIS patients (P=0.0002), compared to normal donors (NI), in Fraction A (fractions 1 to 5; left panel). Compared to normal donors, RT activity was also significantly higher in BC patients (P=0.0063) and DCIS patients (P=0.0003) in Fraction B (fractions 6 to 10; middle panel). RT activity in BC tumor tissues (red color) and uninvolved breast tissues (green color) was compared (right panel). Significantly higher RT activity was observed in tumor tissues (red color) than in matched uninvolved breast tissues.

In addition, HERV-K viral env mRNA or proteins with RT activity localized in gradient centrifugation fractions of cell culture media or patient plasma was detected by RT-PCR using HERV-K primers (data not shown), or by Western blot using anti-HERV-K env monoclonal antibody (6H5; Fig. 4). HERV-K viral env proteins were detected in only BC patient plasma (Fig. 4A), but not in plasma from normal female donors (Fig. 4B). The density of each fraction was labeled. Our data indicate that fractions with higher RT activity indeed express HERV-K.




Fig. 4 Immunoblot was used to detect HERV-K env protein in each fraction. The density of the fraction accompanies each band at the bottom of gel. A) IDC patient plasma (left panel). B) Normal female donor plasma (right panel). HERV-K recombinant fusion protein was used as positive control.

1.3 Identification of infectious viruses: (months 6 to 42)




Fig. 5 Viruses isolated from density gradient fractions (DGFs) of plasma from a patient with IDC having RT activity were labeled to evaluate virus entry into the cell. High RT fractions were labeled with 5dUTP and used for infection. At various time points post-infection, viruses that infected the cells were observed using confocal microscopy. Left panel: control, 8 hr post-infection; Left-center panel: BC virus fraction from plasma, 3 hr post-infection; Center-right panel: BC virus fraction from plasma, 8 hr post-infection; Right panel: BC virus fraction from plasma, 96 hr post-infection. The same DGF obtained from a normal female donor was used as control (8 hr post-infection; Left panel). HERV-K incoming virions were detected by confocal microscope (red color).

We determined the synthesis of infectious viruses in density gradient fractions after ultracentrifugation of plasma obtained from BC patients, and compared to fractions having the same density as that obtained from other cancer patients with high or low RT activity. Plasma samples obtained from women without cancer were used as controls. Viruses were labeled in buffer containing AlexaFluor 546 – dUTP and other reagents necessary for the endogenous reverse transcription (endo-RT) to proceed. Then viruses from plasma (0.2% of the fraction volume) (0.6 µl) or from BC tissues (2% of the fraction volume) (6 µl) were used to infect target cells (C3.555 feline cells) in media containing 4 µg of Polybrene/ml for 3 h at 37°C. Cells were washed and incubated in regular medium for 3h, 8h, or 96 h after infection. Viruses that integrated into target cells were observed between 8 hr and 96 hr (Fig.5C and Fig.5D). This technique in Fig.5 allows us to visualize the viral genome once it is delivered in target cells. We are the first to demonstrate that HERV-K viruses isolated from BC patients with IDC are able to infect target cells. Our data provide strong evidence for infection and activation of HERV-K virus in BC, which may impact BC development and tumorigenesis.

Project 2: To evaluate anti-viral antibodies and viral RNA as detection and progression biomarkers:

2-1 Evaluation of anti-HERV antibodies as biomarkers for BC: (months 3 to 46)

In our grant application, RT-PCR was used to confirm viral load in sera by qRT-PCR, demonstrating that HERV-K viral mRNAs were indeed present in cancer patient sera. Our data indicate that HERV-K antibodies (Fig.6A) and even viral particles are present in BC patient sera, especially in patients with DCIS.




Fig. 6 A) Anti-HERV-K env antibodies were detected at higher levels in BC patient sera (1:200 dilution) at various stages of disease by ELISA using HERV-K env fusion protein (10 µg/ml), compared with normal female controls. **B)** Viral load (HERV-K mRNA copy number) was determined in RNA obtained from patient sera by qRT-PCR. Sera obtained from patients with various stages of breast cancer were assayed. Significantly higher copy numbers of HERV-K viral RNAs were demonstrated in patients with DCIS, stage I, stage IIA, stage IIB, and stage IIIA, compared with normal female donors.

2.2 Determine the viral load as a potential biomarker for early detection: (months 6 to 42)

HERV-K was quantitated by qRT-PCR using HER-K env SU primers from RNA isolated from donor sera from patients with different stages of breast cancer. The viral load was compared with viral load in normal female control sera (Fig. 6B).

Serum antibodies were also detected as markers of viral load. We synthesized and tested several HERV-K multiple antigen peptides (MAPs), which are protease and peptidase resistant, as early detection markers of BC. We compared normal female donors and patients with tumor in situ (TIS). The MAPs-based assays were able to discriminate between TIS and controls (Fig. 7) as well as our HERV-K protein-based assays, suggesting that synthetic peptides can be used instead of HERV-K proteins for detecting serum antibodies in ELISA assays.





Fig. 7 Anti-HERV-K antibodies were detected using various HERV-K multiple antigen peptides (MAPs) (10 µg/ml) in BC patient (tumor in situ, TIS) and normal female control sera (1:200 dilution) by ELISA. Significantly higher titers were observed in TIS patients including MAPs 95-96 (P=0.033), 75-76 (P=0.0136), 92-93 (P=0.0266), and 73 (P=0.006), but not in MAPs 108 and 82-83. The PC+HC group is also a control group (female women without breast cancer).

2.3 Determine whether viral load can be used as a biomarker for predicting BC metastasis: (months 12 to 48)
Recently, sera taken from two groups of BC patients at diagnosis were matched for ER, PR and HER2 status. One group was metastatic BC patients (MBC) who developed metastatic breast cancer 3 years after diagnosis, and the other group (NED) showed no evidence of disease after 3 years. Significantly ($P = 0.0415$) increased expression of HERV-K in MBC (N=56) over NBC (N=56; Fig. 8A) was demonstrated in our lab using the Wilcoxon rank-sum test (Fig. 8). These results validate previous findings from a pilot study, where MBC (N=21) had higher expression than NED (N=21) ($P = 0.034$), and provide strong evidence that HERV-K is a predictive biomarker of metastatic BC. Sites of metastasis of these MBC are shown in Fig. 8B.



2.4 Determine whether HERV-K viruses promote tumor growth:
MCF-10AT cells were transfected with pLVX-Kenv or empty vector (pLVX), to overexpress HERV-K. The expression of HERV-K env RNA and protein in both cell lines was determined by RT-PCR, qRT-PCR, and Western blot (Fig. 9A). Cell proliferation and transformation was determined in both cell lines (Fig. 9B and 9C). Significantly increased proliferation ($p=0.0307$) and colony number ($p<0.0001$) was observed in MCF-10ATpLVX-Kenv compared in the cells transfected pLVX. These results indicate that HERV-K env gene promotes non-cancer cell proliferation and transformation. Our next planned set of experiments will be to determine whether HEDRV-K overexpression promotes tumorigenicity in vivo in mouse models.





Fig. 9 HERV-K env cDNA isolated from infectious viruses was cloned into a pLVX Lentivirus (Lenti) vector and transfected into MCF-10AT cells to generate pLVX-Kenv. MCF-10AT cells transfected with pLVX-Lenti vector only (pLVX) were used as control. **(A)** The expression of HERV-K env RNA was compared between pLVX and pLVX-Kenv, and there was significantly increased expression of HERV-K in MCF-10AT cells transfected with Kenv, compared with cells transfected with vector only ($P=0.0002$). The expression of HERV-K env protein was increased in MCF-10AT cells transfected with pLVX-Kenv, in comparison to MCF-10AT cells transfected with pLVX vector only cells (1.83 fold increased by Image J analysis), by Western blot using anti-HERV-K mAb (6H5). **(B)** Cell proliferation was compared in cells cultured for 3 days post-transfection. A significantly increased cell proliferation ($p=0.0307$) was observed in MCF-10AT cells transfected with pLVX-Kenv than in cells transfected with pLVX only. **(C)** A soft agar assay revealed a significantly higher number of colonies ($p<0.0001$) in MCF-10AT cells transfected with pLVX-Kenv than in the same cell line transfected with vector only.

2.5 Determine whether HERV-K viruses promote metastasis: (months 18 to 46)



After we observed increased proliferation and transformation in MCF-10AT cells (Fig. 9), we further explored HERV-K involvement in tumorigenicity and metastasis. Toward this end, MDA-MB-231 cells were stably transfected with shRNA targeting the HERV-K *env* gene or control shRNA with a scrambled insert (shRNAc). The tumor growth in NOD/SCID gamma female mice was compared in mice xenografted with MDA-MB-231 cells stably transfected with shRNA targeting HERV-K *env* mRNA (shRNAenv), compared with mice injected with control shRNA (shRNAc) (Fig. 10). Significantly reduced tumor sizes (Fig. 10A) and weights (Fig. 10B) were demonstrated in MDA-MB-231 cells stably transfected with shRNAenv compared with shRNAc. These results indicate that HERV-K plays an important role in tumorigenicity. Furthermore, lung metastasis was compared in these mice bearing xenografts of cells transfected with shRNAenv or shRNAc. Lung tissues were harvested from both groups and the number of metastases formed was determined (Fig. 10C). Stronger green fluorescence was observed in pieces of lung tissue from mice injected with MDA-MB-231 cells transfected with shRNAc than with shRNAenv (bottom two panels). More metastatic cells were also observed in MDA-MB-231 cells transfected with shRNAc than with shRNAenv (top two panels).

In addition, MDA-MB-231 or MCF-7 breast cancer cell lines will be transfected with pLVX-Kenv to determine whether HERV-K overexpression promotes tumor growth. Cell proliferation and soft agar assays will be used to determine the changes in growth rates and cell transformation. Also, these cells will be injected through the tail vein and in situ, and metastasis to lung, liver, and other organs will be examined.

2.6 Determine associations of HERV-K with the p53 pathway: (months 8 to 47)

To establish that HERV-K is involved in oncogenic signaling pathways, we propose to investigate p53 and other mechanisms by which HERV-K triggers changes that result in the development of BC. In this Aim, we will continue to explore our finding of p53 involvement in HERV-K signaling, and focus on the p53 pathway in BC cell lines treated with anti-HERV-K monoclonal antibodies or shRNA to down-regulate HERV-K expression. We found that knockdown of HERV-K *env* with shRNA resulted in down-regulation of *H-Ras*, *MDM2* and *c-Myc* mRNAs. *c-Myc* induces the tumor suppressor ARF, which inhibits MDM2 and leads to stabilization of the p53 protein¹⁹. In this grant, qRT-PCR was performed to determine changes in expression of *p53*, *MDM2* and *c-myc* in cancer cell lines stably transfected with shRNA targeting the HERV-K *env* gene, to evaluate whether HERV-K is affecting signaling via the p14ARF/MDM2/p53 axis (Fig. 11A). Changes in expression of these genes at the protein level were also determined using flow cytometry with various antibodies (Fig. 11B). A possible pathway involving HERV-K signaling in cancer is shown in Fig. 11C.




Fig. 11 (A) qRT-PCR was used to determine the changes in expression of several genes including *HERV-K env*, *H-Ras*, *MDM2*, and *TP53* RNAs in cancer cells transfected with shRNA targeting *HERV-K env* RNAs, relative to control shRNA. Down-regulation of *HERV-K env* RNA by shRNA targeting led to down-regulation of *H-Ras*, *MDM2*, and *c-Myc*, and upregulation of *TP53* in cancer cells transfected with shRNA. **(B)** Anti-HERV-K monoclonal antibody (6H5; 10µg/ml) was used to treat various breast cell lines in a single assay and changes in expression of various proteins including *HERV-K*, *Caspases 3, 8, and 9*, *CIDEA*, *TNFSF8*, *TNFRSF10D*, *TP53*, *TP53AIP1*, *GML*, and *MYOD1* were determined. Increased expression of multiple proteins was observed in BC cell lines compared with non-BC cell lines (MCF-10A and MCF10AT), with the exception of *TP53AIP1* in MCF-10A. 6H5 thus has an effect on expression of cancer-relevant proteins in BC cell lines. **(C)** Possible pathways through which anti-HERV-K antibody blocks BC proliferation and progression.

Project 3: HERV-K viral targets for immunotherapy:

3.1. Screening PBMCs from BC patient blood for T-cell responses: (Months 3–42).

An HERV-K specific chimeric antigen receptor (CAR) was generated from an anti-HERV-K single chain antibody generated from anti-HERV-K 6H5 antibody. PBMCs from BC (Fig.12A) or OC patient blood (Fig.12B) or other donors (Fig.12C) that were bearing the CAR were used for adoptive therapy (Fig. 12). MDA-MB-231 cells transfected with shRNA targeting *HERV-K env* RNA (shRNA) or control shRNA (cont) were used as target cells for CTL assays to determine whether or not the cytotoxicity depend on *HERV-K* expression. *HERV-K* specific CAR T cells were cytotoxic toward MDA-MB-231 cells treated with control shRNA, but not cells treated with shRNA targeting *HERV-K env* RNA, which down-regulated *HERV-K env* RNA expression in MDA-MB-231 cells. Our results indicate that *HERV-K* specific CAR killing depends on target cell expression of *HERV-K*.





Fig. 12 *HERV-K* specific CAR cytotoxicity toward breast cancer cells (MDA-MB-231) was determined using a CTL assay. *HERV-K* specific CAR T cells were generated from PBMC cells isolated from BC (Acc108; **A**), OC (Acc153; **B**), and a normal female control (ND#427478; **C**), and were used for CTL assays. MDA-MB-231 breast cancer cells stably transfected with *HERV-K* shRNA (MDAMB231 shRNA) or control shRNA (MDAMB231 control) were used as target cells for the CTL assays. Only MDA-MB-231 control cells, but not MDAMB231 shRNA cells, were killed by *HERV-K* specific CAR T cells obtained from BC, OC, and a normal female donor.

Furthermore, *HERV-K* specific T cells were generated from BC (Fig.13A) or a normal female donor (Fig.13B) and MDA-MB-435eb1 BC cells served as target cells (Fig.13). *HERV-K* specific T cells generated from a BC patient (Fig.13A) showed greater cytotoxicity toward MDA-MB-435eb1 cells than did T cells generated from a

normal female donor (Fig.13B). CD3 and CD8 specific T cells from HERV-K specific T cells were determined by flow cytometry (Fig.13C). These data indicate that greater numbers of HERV-K specific T cells were only generated in BC patients, but not in normal female donors who do not express HERV-K.



3.2. Development of tumor infiltrating lymphocytes for T-cell adoptive therapy: (months 4 to 44)

Tumor specimens from BC surgery patients were collected and tumor infiltrating lymphocytes (TIL) or normal uninvolved tissue infiltrating lymphocytes (NIL) were cultured. Mononuclear cells were cultured and expanded to lymphocytes according to the Statement of Work provided in “Supporting Documentation”. These cells were stored and banked for future use.

3.3. We will generate TCRs that target the HLA-A*0201-restricted epitopes of HERV-K env protein, and we will compare its antitumor effect with HERV-K CARs side-by-side: (months 12 to 46)

- mRNA will be isolated from sorted, highly avid CD8 T cells using a Oligotex Direct mRNA Mini kit.
- the anchor sequence-containing cDNA will be synthesized from the mRNA obtained with a SMARTer PCR cDNA Synthesis kit (Clontech).
- TCR gene amplification will then be performed on the single-stranded cDNA using primers complementary to the TCR constant region and the SMART oligonucleotide.
- The PCR products will be cloned into pCRII vector and the inserts will be sequenced.
- The anti-tumor effects of HERV-K specific CAR vs. HERV-K specific TCR will be compared side-by-side in autologous cancer cells *in vitro* and *in vivo*.

Project 4: Viral activation of the innate immune response in BC: (months 3 to 44)

4.1. Determine if HERV-K modulation effects (Toll-like receptor) TLR and RIG-I-like receptors (RLR) activation and signaling, and if so which TLRs and RLRs.

In this project, we investigate whether or not HERV-K has the ability to activate the innate immune response TLR and RLR families similar to exogenous viruses and other endogenous danger signals. First, the expression of TLR including TLR3 (green), 7 (red), and 9 (red) in various breast cell lines was determined by Western blot and IFS using their antibodies. One result is shown in Fig.14. We will carry out these same assays after cells are infected with HERV-K viruses isolated from BC patients who have elevated RT activity.




Fig. 14 TLRs including TLR3 (green), 7 (red), and 9 (red) were detected by IFS in the breast cell lines MDAMB231, MCF-7, MCF-10AT, and MCF-10A using their antibodies.

4.2. We will assess the effect of HERV-K on antiretroviral genes and retroviral restriction factors in BC and normal breast: (months 4 to 45)

- Analyze the extent to which these restriction factors alter retroviral replication as a function of HERV-K status.
- Express Bst-2/tetherin in 293Tcells, infect the cells with HERV-K and measure recovery of HERV-K from supernatants of tetherin-expressing cells
- Block HERV-K with siRNA to see if the effect on restriction is specific for HERV-K and can reverse tetherin or APOBEC3 restriction.

4.3. We will evaluate changes occurring at very early stages of BC and during BC progression that have an impact on TLRs or RLRs: (months 5 to 46)

- Investigate the relationship between BC stem cells (CSCs) and HERV-K expression, evaluate the influence of HERV-K knockdown on various parameters associated with metastasis, and determine whether TLRs or RLRs are required for HERV-K to exert its effects in CSCs or during metastasis.
- The involvement of Polo-like kinases (Plks) as essential components of antiviral pathways will be determined in vitro and in vivo.




Fig. 15 HERV-K (green fluorescence) and TLR 9 (red) were detected by IFS in the BC cell line MDA-MB-231 to a greater extent than in MCF-10A non-tumorigenic breast cells using their respective antibodies. 6H5 is anti-HERV-K env antibody.

Co-localization (yellow; left panel) of TLR 9 (red; right panel) and HERV-K (green; center panel) was compared in MCF-10A and MDA-MB-231 cells (Fig. 15). Co-localization was prominent in MDA-MB-231 BC cells but not in the transformed but non-tumorigenic breast cell line MCF-10A, which showed low expression of both HERV-K and TLR9. Our data demonstrate for the first time co-expression of TLR9 and HERV-K in cancer cells. TLRs may thus be required for HERV-K to exert its effects on breast tumorigenicity. We will focus on evaluating interactions between TLR9 and HERV-K in upcoming studies.

Project 5: Fully human anti-viral antibody for BC:

5.1. We will develop rapid screening of high-affinity, highly cytotoxic human antibodies against BC from the memory B-cells of pre-screened BC patients using nanowell screening: (months 3 to 40)

In this project, a microengraving technique for validation of cytotoxicity of antibodies has been developed in our lab (see Fig. 16A). Anti-HERV-K mAb 6H5 hybridoma cells were used for testing our hypothesis before using memory B cells from BC patients. Single hybridoma cells were added single MDA-MB-231 cells and a CYTOX marker was used for measuring cytotoxicity. Single 6H5 hybridoma cells that included A1, A7, B3, B5, and C3 were selected as depicted in Fig. 16A and PCR was carried out as in Fig. 16B. Sequence analysis was further employed to confirm their sequences (data not shown).




Fig. 16 (A) A nanowell screen has been developed in our lab which can rapidly screen for high-affinity single cell antibodies. Single cells obtained from 6H5 hybridoma cells were tested using this method. The single cells A1, A7, B3, B5, and C3 were selected using nanowell screening for their ability to kill target MDA-MB-231 BC cells. **(B)** Heavy chain and light chain fragments from the above single cells were produced by PCR using their primers, with the exception in C3, for which the light chain is missing.

- Using standard single-cell RT-PCR techniques we will amplify and clone the paired variable regions corresponding to these antibodies.

5.2. We will carry out molecular characterization of human anti-HERV-K env antibodies and quantify effector functionality *in vitro* using BC cell lines: (months 6 to 46)

- Clone into an Ig expression vector carrying the constant region of human $\gamma 1$, C κ , and C λ , sequence and transiently express in 293T cells.
- We will carry out standard characterization (ELISA/Biacore) (for affinity measurement).
- We will quantify antibody dependent cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) using annexin V and caspase assays and antibody mediated induction of apoptosis using caspase assays.

5.3. We will characterize therapeutic antibodies in a mouse model for BC: (months 12 to 46)

- Anti-tumor effects of human anti-HERV-K monoclonal antibodies (mAbs) will be tested *in vitro* and *in vivo*.
- Multiple assays will be carried out to determine the relationship between the expression of HERV-K env protein after treatment with human or murine anti-HERV-K antibodies (or control antibodies) and cell growth, apoptosis and tumorigenic potential of BC cell lines (soft agar assay).